Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Validation of genetic case-control studies in AIDS and application to the CX3CR1 polymorphism

Article Abstract:

More research on larger groups of patients is needed to determine whether the gene for the CX3CR1 HIV-1 receptor can confer resistance to HIV infection. This has been shown in some studies of long-term non-progressors.

Author: An, Ping, Hendel, Houria, Winkler, Cheryl, Roemer-Binns, Elisabeth, Nelson, George, Haumont, Philippe, O'Brien, Steve, Khalilli, Kamel, Zagury, Daniel, Rappaport, Jay, Zagury, Jean-Francois
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2001
Health aspects, Genetic polymorphisms

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression

Article Abstract:

The relative contributions to AIDS progression of CCR2 641, CCR5 delta32, and CCR5 promoter haplotype +.P1.+ in the GRIV cohort, which included patients representing the extremes of the distribution for AIDS progression are reported. The comparison of subjects progressing in the first three years after HIV-1 infection with average progressors showed that CCR5 dellta32 and CCR5 P1 have a strong influence early in HIV-1 infection.

Author: Carrington, Mary, Vlahov, David, Phair, John, Ping An, Jacobson, Lisa P., O'Brien, Stephen J., Winkler, Cheryl A., Hendel, Houria, Rappaport, Jay, Zagury, Jean-Francois, Andrieu, Jean-Marie, Smith, Michael W., Wei Lu, Therwath, Amu, Schachter, Francois, Nelson , George W., Bertin-Maghit, Sebastien, Vasilescu, Alexandre
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2004
United States, Science & research, Research, Genetic aspects, Haplotypes

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Tat toxoid as a component of a preventive vaccine in seronegative subjects

Article Abstract:

A vaccine against the Tat protein of HIV may prevent the virus from destroying a patient's imune system. This protein is believed to cause the immunosuppression that is seen in HIV patients. Researchers vaccinated five HIV-negative people with an anti-Tat vaccine called Tat toxoid. All five people developed antibodies against Tat and also had an increased T cell response to the protein.

Author: Zagury, Daniel, Rappaport, Jay, Zagury, Jean-Francois, Gallo, Robert C., Gringeri, Alessandro, Santagostino, Elena, Muca-Perja, Myrvet, Le Buanec, Helene, Bizzini, Bernard, Lachgar, Abderrhaim, Burny, Arsene
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
Subject: Health
ISSN: 1077-9450
Year: 1999
Testing, AIDS vaccines

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Development and progression, HIV infection, HIV infections
Similar abstracts:
  • Abstracts: Diagnostic imaging in the evaluation of suspected aortic dissection: old standards and new directions. The International Registry of Acute Aortic Dissection (IRAD)
  • Abstracts: Gamma secretase-medicated Notch signaling worsens brain damage and functional outcome in ischemic stroke. Activin to the rescue for overexcited neurons
  • Abstracts: Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population
  • Abstracts: Cytokine profile and immunomodulation in asymptomatic human T-lymphotropic virus type 1-infected blood donors
  • Abstracts: High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.